ABSTRACT
The conceptual appeal of “pay-for-performance” or “risk-sharing” agreements is understandable. The agreements offer an innovative payment model under which payers reimburse manufacturers on the basis of health outcomes achieved rather than products provided [1–3]. In theory, the effects of these arrangements can be far-reaching, promising to improve population health and drive system wide efficiencies [1,4].